P. Waldmeier

发表

Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 andR-(−)-Deprenyl*

P. Fürst, J. van Oostrum, K. Zimmermann, 1998, The Journal of Biological Chemistry.

Presynaptic GABA Receptors

P. Waldmeier, P. Baumann, 1990, Annals of the New York Academy of Sciences.

NIM811, a Mitochondrial Permeability Transition Inhibitor, Prevents Mitochondrial Depolarization in Small‐for‐Size Rat Liver Grafts

T. Theruvath, J. Lemasters, P. Waldmeier, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Effects of baclofen on dopamine metabolism and interaction with neuroleptic effects.

P. Waldmeier, L. Maître, 1978, European Journal of Pharmacology.

The Dopaminergic System in the Hippocampus: Site of Action for Antipsychotic Activity of Neuroleptics?

P. Waldmeier, S. Bischoff, A. Vassout, 1986 .

Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain).

P. Waldmeier, 1987, Journal of neural transmission. Supplementum.

An automated fluorometric method for the estimation of dopamine in brain tissue extracts.

P. Waldmeier, L. Maître, 1973, Analytical biochemistry.

The Nonimmunosuppressive Cyclosporin Analogs NIM811 and UNIL025 Display Nanomolar Potencies on Permeability Transition in Brain-Derived Mitochondria

E. Elmér, M. Hansson, U. Ruegg, 2004, Journal of bioenergetics and biomembranes.

Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo.

A. Steulet, P. Waldmeier, A. Buchle, 1993, Biochemical pharmacology.

Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.

P. Waldmeier, L. Maître, P. De Herdt, 1990, Journal of neural transmission. Supplementum.

Relations Between the Degree of Monoamine Oxidase Inhibition and Some Psychopharmacological Responses to Monoamine Oxidase Inhibitors in Rats

A. Delini-Stula, P. Waldmeier, L. Maître, 2008 .

On the Interaction Carbamazepine with Catecholamine Metabolism: Implication for Psychopharmacological and Behavioural Effects

P. Waldmeier, P. Baumann, L. Maître, 1985 .

Neurorescuing effects of the GAPDH ligand CGP 3466B.

A. Cools, W. Tatton, P. Waldmeier, 2000, Journal of neural transmission. Supplementum.

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease

W. Spooren, B. Hengerer, P. Waldmeier, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

Clozapine: reduction of the initial dopamine turnover increase by repeated treatment.

P. Waldmeier, L. Maître, 1976, European journal of pharmacology.

Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity.

W. Spooren, P. Waldmeier, A. Vassout, 1998, European journal of pharmacology.

Release of endogenous glutamate from rat cortical slices in presence of the glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid

P. Waldmeier, P. Wicki, J. Feldtrauer, 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

Increased dopamine metabolism in rat striatum after infusions of substance P into the substantia nigra

P. Waldmeier, R. Kam, K. Sto¨cklin, 1978, Brain Research.

Neurochemical investigations of the interaction of N,N-dimethyltryptamine with the dopaminergic system in rat brain

P. Waldmeier, L. Maître, 1977, Psychopharmacology.

Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism

P. Waldmeier, L. Maître, P. C. Waldmeier, 1976, Naunyn-Schmiedeberg's Archives of Pharmacology.

CGP 6085 A, a new, specific, inhibitor of serotonin uptake: neurochemical characterization and comparison with other serotonin uptake blockers.

P. Waldmeier, P. Baumann, L. Maître, 1979, The Journal of pharmacology and experimental therapeutics.

An orally active anti‐apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease

Y. Sagot, P. Waldmeier, N. Toni, 2000, British journal of pharmacology.

Cyclophilin D as a drug target.

J. Lemasters, K. Zimmermann, T. Qian, 2003, Current medicinal chemistry.

Antagonism of baclofen's effects on rat striatal 5‐HT metabolism: A model for 5‐HT agonistic properties?

P. Waldmeier, B. Fehr, 1982 .

Analysis of the activation of dopamine metabolism by a serotonin uptake inhibitor.

P. Waldmeier, 1979, European journal of pharmacology.

AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY

P. Waldmeier, P. Baumann, L. Maître, 1980, Acta psychiatrica Scandinavica.

M. Schmutz, P. Waldmeier, C. Stierlin, 1995, Neurology.

Cumulative effects of irreversible MAO inhibitors in vivo.

P. Waldmeier, A. Felner, 1979, Biochemical pharmacology.

The treatment of iron overload — psychiatric implications

P. Waldmeier, V. Berdoukas, M. Struck, 1993 .

Endogenous dopamine (DA) modulates [3H]spiperone binding in vivo in rat brain.

P. Waldmeier, S. Bischoff, M. Heinrich, 1991, Journal of receptor research.

Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A.

K. Leenders, S. Ametamey, A. Antonini, 1996, Nuclear medicine and biology.

Simultaneous measurement of Ca2+ transients and of membrane depolarizations in synaptosomes.

M. Ochsner, P. Waldmeier, T. Fleck, 1991, Biochemical and biophysical research communications.

Biphasic effects of some dopamine agonists on striatal acetylcholine concentrations.

P. Waldmeier, 1983, European journal of pharmacology.

Alteration of central alpha2- and beta-adrenergic receptors in the rat after DSP-4, a selective noradrenergic neurotoxin

P. Waldmeier, H. Bittiger, S. Bischoff, 1983, Neuroscience.

Simultaneous automated estimation of noradrenaline and dopamine in brain tissue.

P. Waldmeier, L. Maître, P. De Herdt, 1974, Clinical chemistry.

The dimerization, polymerization, and hydrolysis of FeIII-4,4′,4″,4″′-tetrasulfophthalocyanine

B. Prijs, H. Sigel, P. Waldmeier, 1971 .

The inhibition of monoamine oxidase by brofaromine.

K. Tipton, P. Waldmeier, M. Anderson, 1991, Biochemical pharmacology.

ON THE RELEVANCE OF PREFERENTIAL INCREASES OF MESOLIMBIC VERSUS STRIATAL DOPAMINE TURNOVER FOR THE PREDICTION OF ANTIPSYCHOTIC ACTIVITY OF PSYCHOTROPIC DRUGS

P. Waldmeier, L. Maître, P. C. Waldmeier, 1976, Journal of neurochemistry.

The effects of 5-HT uptake- and MAO-inhibitors on l-5-HTP-induced excitation in rats

A. Delini-Stula, P. Waldmeier, R. Ortmann, 1980, Naunyn-Schmiedeberg's Archives of Pharmacology.

3-methoxytyramine: Its suitability as an indicator of synaptic dopamine release

W. Richter, P. Waldmeier, W. Blum, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

CGP 4718 A, a new potential antidepressant with a dual mode of action.

K. Tipton, P. Waldmeier, R. Bernasconi, 1984, European journal of pharmacology.

On the role of α-methyldopamine in the antihypertensive effect of α-methyldopa

P. Waldmeier, L. Maître, P. Hedwall, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

3,4-Dihydroxyphenylacetic acid (DOPAC) as an index of noradrenaline turnover: Effects of hydergine® and vincamine

P. Waldmeier, L. Maître, Dr. O. Boulat, 2005, Journal of Neural Transmission / General Section JNT.

METAL IONS AND HYDROGEN PEROXIDE XXIX. On the Kinetics and Mechanism of the Catalase-like Activity of Nickel(II) and Nickel(II)-Amine Complexes

H. Sigel, P. Waldmeier, R. Griesser, 1974 .

Inhibition of the catalase-like activity of cobalt(III)-hematoporphyrin by amino acids, adenine and related ligands Stability of the inhibitor adducts

H. Sigel, P. Waldmeier, 1973 .

Specific γ‐hydroxybutyrate‐binding sites but loss of pharmacological effects of γ‐hydroxybutyrate in GABAB(1)‐deficient mice

J. Cryan, B. Bettler, W. Froestl, 2003 .

Urinary Excretion of Tryptamine in Comparison to Normetanephrine and Beta-Phenylethylamine in Human Volunteers After Subchronic Treatment with Different Monoamine Oxidase Inhibitors

P. Bieck, P. Waldmeier, E. Nilsson, 1984 .

The monoamine oxidase inhibiting properties of CGP 11305 A.

K. Tipton, P. Waldmeier, A. Felner, 1983, European journal of pharmacology.

Displacement of striatal 5‐hydroxytryptamine by dopamine released from endogenous stores

P. Waldmeier, 1985, The Journal of pharmacy and pharmacology.

Mechanisms of action of lithium in affective disorders: a status report.

P. Waldmeier, 1990, Pharmacology & toxicology.

The measurement of the release of endogenous GABA from rat brain slices by liquid chromatography with electrochemical detection

P. Waldmeier, P. Baumann, P. Wicki, 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

Metal ions and hydrogen peroxide. XXIV. On the kinetics and mechanism of the catalase-like activity of the Fe3+ complex of 4,4′,4″,4‴-tetrasulfophthalocyanine

H. Sigel, P. Waldmeier, 1971 .

Ifoxetine, a compound with atypical effects on serotonin uptake.

P. Waldmeier, H. Bittiger, S. Bischoff, 1986, European journal of pharmacology.

The effects of amfonelic acid on 5-HT metabolism in rat brain

P. Waldmeier, A. Buchle, J. Feldtrauer, 2005, Journal of Neural Transmission.

Brofaromine — a review of its pharmacological properties and therapeutic use

H. Möller, H. Volz, C. Gleiter, 2005, Journal of Neural Transmission.

Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum

P. Waldmeier, J. Feldtrauer, K. Stöcklin, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

CSF monoamine metabolites in schizophrenic patients

W. Gattaz, H. Beckmann, P. Waldmeier, 1982, Acta psychiatrica Scandinavica.

Modulation of dopaminergic transmission by alpha-noradrenergic agonists and antagonists: Evidence for antidopaminergic properties of some alpha antagonists

P. Waldmeier, S. Bischoff, R. Ortmann, 1982, Experientia.

Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1, receptor subtypes in the rat brain

M. Williams, P. Waldmeier, S. Bischoff, 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

Further evidence for negative feedback control of serotonin release in the central nervous system

P. Waldmeier, P. Baumann, 1981, Naunyn-Schmiedeberg's Archives of Pharmacology.

Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer.

P. Waldmeier, P. Baumann, A. Storni, 1982, Biochemical pharmacology.

Ca2+-dependent release of endogenous GABA from rat cortical slices from different pools by different stimulation conditions

P. Waldmeier, P. Baumann, P. Wicki, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811.

John J Lemasters, J. Lemasters, T. Qian, 2002, Molecular pharmacology.

Mitochondrial permeability transition in CNS trauma: Cause or effect of neuronal cell death?

Alexander Sasha Rabchevsky, P. Sullivan, P. Waldmeier, 2005, Journal of neuroscience research.

Amine oxidases and their endogenous substrats

P. Waldmeier, 1987 .

Serotonin--dopamine interactions in the nigrostriatal system.

A. Delini-Stula, P. Waldmeier, 1979, European journal of pharmacology.

Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors.

A. Delini-Stula, P. Waldmeier, E. Radeke, 1988, Psychopharmacology series.

Effects of clomipramine and other tricyclic antidepressants on biogenic amine uptake and turnover.

P. Waldmeier, P. Greengrass, P. Baumann, 1976, Postgraduate medical journal.

Chiral antidepressants: a potential help in antidepressant and behavioural research

P. Waldmeier, 1983 .

METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAO B IN THE RAT BRAIN IN VIVO

P. Waldmeier, L. Maître, J. Feldtrauer, 1977, Journal of neurochemistry.

Hyperdopaminergia and altered locomotor activity in GABAB1‐deficient mice

D. Hoyer, P. Pévet, M. Gassmann, 2006, Journal of neurochemistry.

Urinary phenylethylamine correlates positively with hypomania, and negatively with depression, paranoia, and social introversion on the MMPI

H. Beckmann, P. Waldmeier, H. Moises, 2004, European archives of psychiatry and neurological sciences.

Effects of baclofen and γ-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism

P. Waldmeier, B. Fehr, 1978 .

On the role of O-methylation in the metabolism of S-adenosylmethionine in rat brain.

P. Waldmeier, J. Feldtrauer, 1987, Biochemical pharmacology.

Is There a Common Denominator for the Antimanic Effect of Lithium and Anticonvulsants?

P. Waldmeier, 1987, Pharmacopsychiatry.

A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse

A. Young, D. Housman, S. Hersch, 2007, Proceedings of the National Academy of Sciences.

Carbamazepine decreases catecholamine turnover in the rat brain.

P. Waldmeier, P. Baumann, L. Maître, 1984, The Journal of pharmacology and experimental therapeutics.

Preferential deamination of dopamine by an A type monoamine oxidase in rat brain

A. Delini-Stula, P. Waldmeier, L. Maître, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A

K. Antonin, P. Bieck, P. Waldmeier, 2004, European Journal of Clinical Pharmacology.

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.

D. Bozyczko‐Coyne, Michael Williams, P. Waldmeier, 2006, Biochemical pharmacology.

Chapter 21 – An Assessment of the Chances of Antiapoptotic Drug Therapy in Patients with Neurodegenerative Disorders

P. Waldmeier, 2007 .

Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants.

P. Waldmeier, S. Bischoff, A. Vassout, 1993, Journal of receptor research.

Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment.

P. Waldmeier, H. Bittiger, S. Bischoff, 1984, European journal of pharmacology.

Selective inhibition of noradrenaline and serotonin uptake by C 49802-B-Ba and CGP 6085 A.

P. Waldmeier, R. Bernasconi, M. Wilhelm, 1977, European journal of pharmacology.

Prospects for antiapoptotic drug therapy of neurodegenerative diseases

P. Waldmeier, 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine

P. Waldmeier, 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A role for computer simulation in solving the riddles of autoreceptor-mediated regulation of GABA release

P. Waldmeier, P. Baumann, T. Christen, 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

Reversibility of the interaction of CGP 11305 A with MAO A in vivo.

P. Waldmeier, E. Paul, J. Feldtrauer, 1983, European journal of pharmacology.

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors

P. Waldmeier, R. Ortmann, M. Schaub, 2004, Psychopharmacology.

Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis

A. Steulet, P. Waldmeier, P. Wicki, 1993, Neurochemical Research.

Metaraminol uptake by human thrombocytes: A poor model for neuronal noradrenaline uptake

P. Waldmeier, P. Baumann, 1977, Experientia.

Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum

M. Schmutz, P. Waldmeier, P. Martin, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Comparison of the effects of maprotiline (ludiomil) and clomipramine (anafranil) on serotonin uptake and tryptophan-binding in plasma.

P. Waldmeier, P. Greengrass, P. Imhof, 1976, Biological psychiatry.

Autoreceptor-mediated regulation of GABA release: role of uptake inhibition and effects of novel GABAB antagonists

P. Waldmeier, P. Baumann, P. Wicki, 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls

G. Reynolds, P. Riederer, W. Gattaz, 1982, Archiv für Psychiatrie und Nervenkrankheiten.

Antidepressants: dopamine's turn now?

P. Waldmeier, 1982 .

Transgenic Activation of Ras in Neurons Promotes Hypertrophy and Protects from Lesion-Induced Degeneration

E. Wagner, K. Lingenhöhl, P. Wahle, 2000, The Journal of cell biology.

Inhibition and activation of enzymatic transfer of the methyl group from 5-methyltetrahydrofolate to tryptamine by catecholamine metabolites and analogues.

P. Waldmeier, L. Maître, J. Feldtrauer, 1975, Biochemical pharmacology.

The effects of single and repeated doses of maprotiline, oxaprotiline and its enantiomers on foot-shock induced fighting in rats

A. Delini-Stula, C. Boissard, P. Waldmeier, 1983, Pharmacology Biochemistry and Behavior.

Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release

S. Urwyler, K. Kaupmann, P. Waldmeier, 2008, Journal of Neural Transmission.

Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice.

J. Cryan, B. Bettler, W. Froestl, 2003, The European journal of neuroscience.

Short- and long-term survival of surgical colic patients. Small intestinal resection does not influence the prognosis of horses with small intestinal colic following their first laparotomy

K. Rohn, P. Waldmeier, K. Feige, 2009 .

Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?

W. Tatton, P. Waldmeier, 2004, Drug discovery today.

Monoamine oxidase inhibition in brain and liver of rats treated with chlordimeform.

P. Waldmeier, L. Maître, W. Kehr, 1978, Journal of agricultural and food chemistry.

Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.

A. Glatt, P. Waldmeier, H. Bittiger, 1993, Clinical neuropharmacology.

Morpholin-2-yl-phosphinic acids are potent GABA(B) receptor antagonists in rat brain.

D. Kerr, W. Froestl, P. Waldmeier, 1998, European journal of pharmacology.

Glutamate-induced activation of rat locus coeruleus increases CA1 pyramidal cell excitability

M. Pozza, P. Waldmeier, H. Olpe, 1985, Neuroscience Letters.

Effect of maprotiline, a new antidepressant drug, on serotonin uptake.

P. Waldmeier, P. Baumann, M. Staehelin, 1974, Advances in biochemical psychopharmacology.

Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS

P. Waldmeier, J. Lauber, 2005, Journal of Neural Transmission.

Cerebral 2-Phenylethylamine Concentrations and Turnover not Influenced by Various Pharmacological Treatments in Rats

P. Waldmeier, A. Buchle, J. Lauber, 1985 .

Stereospecificity of behavioural and biochemical responses to oxaprotiline--a new antidepressant.

A. Delini-Stula, P. Waldmeier, H. Olpe, 1982, Advances in biochemical psychopharmacology.

Serotoninergic modulation of mesolimbic and frontal cortical dopamine neurons

P. Waldmeier, Peter C. Waldmeier, 1980, Experientia.

Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain

P. Waldmeier, P. Baumann, 1983, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effects of the putative P-type calcium channel blocker, R,R-(−)-daurisoline on neurotransmitter release

P. Waldmeier, H. Bittiger, P. Wicki, 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

Interactions of Cipazoxapine, Citatepine, Eresepine, and Maroxepine with Central Dopamine (DA) Receptors: Effects on in Vivo (3H)Spiperone Binding, DA Metabolism, and Behavioral Parameters

A. Delini-Stula, P. Waldmeier, S. Bischoff, 1986 .

Protective effects of NIM811 in transient focal cerebral ischemia suggest involvement of the mitochondrial permeability transition.

L. Pettigrew, S. Craddock, C. Pocernich, 2007, Journal of neurotrauma.

5-HT uptake inhibitors: psychopharmacological and neurobiochemical criteria of selectivity.

P. Waldmeier, P. Baumann, L. Maître, 1982, Advances in biochemical psychopharmacology.

Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.

Milen Blagoev, Michael Honer, Bastian Hengerer, 2006, Nuclear medicine and biology.

Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release

S. Urwyler, K. Kaupmann, P. Waldmeier, 2009, Journal of Neural Transmission.

Effects of antidepressant drugs on dopamine uptake and metabolism

P. Waldmeier, 1982, The Journal of pharmacy and pharmacology.

The effect of a subchronic post-lesion treatment with (−)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine

W. Spooren, P. Waldmeier, C. Gentsch, 1999, Journal of Neural Transmission.

A clinical test of noradrenergic involvement in the therapeutic mode of action of an experimental antidepressant

R. Katz, P. Landau, P. Waldmeier, 1993, Biological Psychiatry.

Phenylethylamine and monoamine metabolites in CSF of schizophrenics: Effects of neuroleptic treatment

W. Gattaz, H. Beckmann, P. Waldmeier, 2005, Journal of Neural Transmission.

GABA and glutamate release affected by GABAB receptor antagonists with similar potency: no evidence for pharmacologically different presynaptic receptors

P. Waldmeier, H. Bittiger, P. Baumann, 1994, British journal of pharmacology.

Discrimination of neuroleptics by means of their interaction with amfonelic acid: an attempt to characterize the test.

P. Waldmeier, H. Huber, M. Heinrich, 1985, Biochemical pharmacology.

Stimulation of central serotonin turnover by β-adrenoceptor agonists

P. Waldmeier, 1981, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effects of baclofen on striatal 5-HT mediated by the nigrostriatal dopamine system.

P. Waldmeier, J. Feldtrauer, R. Kam, 1979, European journal of pharmacology.

Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.

A. Delini-Stula, P. Waldmeier, R. Bernasconi, 1983, Modern problems of pharmacopsychiatry.

CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure

P. Waldmeier, H. Bittiger, S. Bischoff, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

Release of endogenous GABA from the substantia nigra is not controlled by GABA autoreceptors

P. Waldmeier, P. Baumann, P. Wicki, 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

Systemic administration of baclofen and the GABAB antagonist, CGP 35348, does not affect GABA, glutamate or aspartate in microdialysates of the striatum of conscious rats

P. Waldmeier, J. Feldtrauer, K. Stöcklin, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effects of some tetrahydrocannabinols on the biosynthesis and utilisation of catecholamines in the rat brain

P. Waldmeier, P. Baumann, L. Maître, 1974 .

On the reversibility of reversible MAO inhibitors

P. Waldmeier, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

Negative feedback control of serotonin release in vivo: Comparison of 5-hydroxyindolacetic acid levels measured by voltammetry in conscious rats and by biochemical techniques

P. Waldmeier, P. Baumann, 1984, Neuroscience.

Pharmacological Profiles of Four New Tetracyclic Dopamine Antagonists, Maroxepine, Citatepine, Eresepine, and Cipazoxapine

A. Delini-Stula, P. Waldmeier, H. Bittiger, 1986 .

Noradrenergic Transmission in Depression: Under- or Overfunction?

P. Waldmeier, 1981, Pharmacopsychiatria.

GABAB receptor antagonists:New tools and potential new drugs

W. Froestl, M. Pozza, P. Waldmeier, 1996 .

Brofaromine - a Selective, Reversible, and Short-Acting MAO-A Inhibitor: Review of the Pharmacological and Clinical Findings

P. Waldmeier, G. Wendt, H. Möller, 1991, Pharmacopsychiatry.

Antisense Peptides: Tools for Receptor Isolation? Lack of Antisense MSH and ACTH to Interact with their Sense Peptides and to Induce Receptor-Specific Antibodies

A. Gerbes, T. Barth, P. Waldmeier, 2011 .

The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, γ-butyrolactone and HA 966 on rat striatal dopamine synthesis

P. Waldmeier, 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

Experimentally induced supersensitivity of neocortical neurons to microiontophoretically administered serotonin

P. Waldmeier, H. Olpe, R. Ortmann, 1981, Brain Research.

Clinical pharmacology of the new COMT inhibitor CGP 28 014

K. Antonin, P. Dostert, G. Farger, 1993, Neurochemical Research.

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.

P. Waldmeier, A. Felner, 1978, Biochemical pharmacology.

Investigations on GABAB receptor-mediated autoinhibition of GABA release

P. Waldmeier, C. Stierlin, P. Baumann, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

INFUSION OF SUBSTANCE P INTO RAT SUBSTANTIA NIGRA INCREASES DOPAMINE METABOLISM IN THE STRIATUM

P. Waldmeier, R. Kam, K. Stöcklin, 1979 .

3,4-Dihydroxyphenylacetic acid (DOPAC): a possible endogenous inhibitor of indoleamine-N-methylation in the rat brain

P. Waldmeier, L. Maître, 1974, Experientia.

α‐Methyldopa, An Unnatural Aromatic Amino Acid

P. Waldmeier, L. Maître, P. Hedwall, 2008 .

Phenylethylamine and Personality

P. Waldmeier, H. Moises, H. Beckmann, 1985 .

Effects of baclofen on striatal dopamine and serotonin metabolism

P. Waldmeier, J. Feldtrauer, B. Fehr, 1980, Brain Research Bulletin.